Discover trends, market shifts, and competitive outlooks for the eylea industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#What Is the Current and Projected Market Size of the Eylea Market Through 2034?

Over the past few years, the eylea market has seen consistent growth. The market size, which sits at $8.09 billion in 2024, is forecasted to rise to $8.49 billion in 2025, registering a compound annual growth rate (CAGR) of 4.9%. The driving forces behind this historical growth include the prevalence of diabetic macular edema (DME), the therapy’s proven clinical efficacy and safety, its competition with other anti-VEGF therapies, regulatory approval for a range of retinal conditions, and a shift in favour of intravitreal injections.

In the ensuing years, it is anticipated that the eylea market size will experience robust growth. The projection for 2029 is a rise to $10.75 billion, with a compound annual growth rate (CAGR) of 6.1%. Factors such as emerging therapeutic indicators, the arrival of biosimilar rivals, heightened awareness and diagnostics, substantial real-world proofs, and analysis post-market studies, and patient’s preference for less regular injections contribute to this growth during the forecast period. The period is also expected to see trends such as advancements in imaging technology, the advent of telemedicine and remote surveillance, patient aid programs, developments in medication delivery technology, retinal imaging technology, and clinical trials geared towards new indications.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9155&type=smp

What Are the Major Market Drivers Behind the Rising Adoption of Eylea Market?

The Eylea market is anticipated to be driven by the rising occurrence of ocular diseases. Such diseases impair the eyes’ functioning and can adversely impact vision clarity. Often, these conditions progress significantly before exhibiting any symptoms. Eylea offers treatment for ocular diseases including wet age-related macular degeneration (AMD) and glaucoma, both of which can damage the retina or macula and compromise vision. This product acts by inhibiting a protein responsible for forming new, weaker blood vessels, and reduces swelling in the retina induced by blocked blood vessels. In the context of this, the BrightFocus Foundation, a nonprofit organization- dedicated to promoting research for macular degeneration and glaucoma from the US, reported in October 2022 that the count of individuals suffering from glaucoma globally stood at 80 million, and projected this to surge to over 111 million by 2040. Consequently, the escalating incidence of ocular diseases is fuelling the Eylea market.

Which Key Market Segments Comprise the Eylea Market and Drive Its Revenue Growth?

The eylea market covered in this report is segmented –

1) By Product: Prefilled Syringe Package, Vial Package

2) By Disorder: Wet Age-Related Macular Degeneration (AMD), Diabetic Retinopathy, Other Disorders

3) By Application: Hospitals, Retail Pharmacy, Other Applications

Subsegments:

1) By Prefilled Syringe Package: Single-Dose Prefilled Syringes, Multi-Dose Prefilled Syringes

2) By Vial Package: Single-Dose Vials, Multi-Dose Vials

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=9155&type=smp

Which Areas Are Leading Regions in the Eylea Market Expansion Across the Globe?

North America was the largest region in the eylea market in 2024. Asia-Pacific is expected to be the fastest-growing region in the eylea market during the forecast period. The regions covered in the eylea market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Are the Strategic Trends Steering theEylea Market Direction?

The eylea market is seeing significant growth due to the increasing focus on research and development. Major players in the industry are showing a heightened interest in producing innovative technical solutions for eylea. For instance, in August 2023, US-based biotech company Regeneron Pharmaceuticals, Inc., known for its work on serious diseases, earned approval from the US FDA for its Eylea HD (aflibercept) injection 8 mg. This treatment is designed for patients dealing with wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR). The administration protocol requires an early period of weekly doses for the first three months in all cases, before moving on to adjusted intervals of eight to 16 weeks for wAMD and DME cases, and eight to 12 weeks for patients with diabetic retinopathy.

View the full report here:

https://www.thebusinessresearchcompany.com/report/eylea-global-market-report

How Is the Eylea Market Conceptually Defined?

Eylea is a type of drug injected into the eye that helps slow vision loss and certain other diseases by blocking the leaking and growth of fluid from abnormal blood vessels from the back of the eye. It is used to treat age-related macular degeneration (AMD).

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9155

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model